Carle Foundation Hospital
- Type
- Teaching hospital
- Where
- Urbana, IL
- Medicare CCN
- 140091
- Received
- $495,188 in 208 records, 2020 ($8,554 general, $486,633 research)
- Source
- CMS Open Payments search ↗
On this site
- Federal award recipient: THE CARLE FOUNDATION HOSPITAL Fuzzy (name and state)
- Lobbying client: CARLE FOUNDATION HOSPITAL Fuzzy (name and state)
- Trademark owner: The Carle Foundation Hospital Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 11 | $8,554 |
| 2020 | Research payment | 197 | $486,633 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 197 | $486,633 |
| Space rental or facility fees (teaching hospital only) | 5 | $5,750 |
| Charitable Contribution | 3 | $1,932 |
| Gift | 1 | $605 |
| Education | 2 | $266 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | Daiichi Sankyo Inc. | $694 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | ENVISAGE | 2020 |
| 2020-12-31 | Daiichi Sankyo Inc. | $642 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | ENVISAGE | 2020 |
| 2020-12-30 | ABBVIE INC. | $1,204 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-234 | 2020 |
| 2020-12-30 | ABBVIE INC. | $192 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-533 | 2020 |
| 2020-12-22 | SEAGEN INC. | $231 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2020 |
| 2020-12-18 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-12-15 | Roche Products Limited | $918 | Research payment | Cash or cash equivalent | Drug | CROHN S DISEASE PROGRAM OLE | 2020 |
| 2020-12-11 | ABBVIE INC. | $325 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-533 | 2020 |
| 2020-12-11 | Merck Sharp & Dohme LLC | $60 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-12-11 | Merck Sharp & Dohme LLC | $30 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-12-09 | Regeneron Pharmaceuticals, Inc. | $821 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS | 2020 |
| 2020-12-09 | Regeneron Pharmaceuticals, Inc. | $821 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS | 2020 |
| 2020-12-09 | ABBVIE INC. | $250 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-675 | 2020 |
| 2020-12-09 | ABBVIE INC. | $250 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-533 | 2020 |
| 2020-12-08 | Eisai Inc. | $3,089 | Research payment | Cash or cash equivalent | Fycompa Drug, Neurology | A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial With an Open-Label Extension Phase of Perampanel as Ad | 2020 |
| 2020-12-08 | Eisai Inc. | $3,089 | Research payment | Cash or cash equivalent | Fycompa Drug, Neurology | A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial With an Open-Label Extension Phase of Perampanel as Ad | 2020 |
| 2020-12-08 | Eisai Inc. | $1,734 | Research payment | Cash or cash equivalent | Fycompa Drug, Neurology | A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial With an Open-Label Extension Phase of Perampanel as Ad | 2020 |
| 2020-12-08 | Eisai Inc. | $1,415 | Research payment | Cash or cash equivalent | Fycompa Drug, Neurology | A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial With an Open-Label Extension Phase of Perampanel as Ad | 2020 |
| 2020-12-08 | Eisai Inc. | $1,321 | Research payment | Cash or cash equivalent | Fycompa Drug, Neurology | A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial With an Open-Label Extension Phase of Perampanel as Ad | 2020 |
| 2020-12-07 | ABBVIE INC. | $1,540 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-533 | 2020 |
| 2020-12-04 | Allergan, Inc. | $1,000 | Research payment | Cash or cash equivalent | AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety o | 2020 | |
| 2020-12-04 | Allergan, Inc. | $1,000 | Research payment | Cash or cash equivalent | AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety o | 2020 | |
| 2020-12-04 | Allergan, Inc. | $1,000 | Research payment | Cash or cash equivalent | AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety o | 2020 | |
| 2020-12-02 | PFIZER INC. | $1,750 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-12-02 | PFIZER INC. | $1,750 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-12-01 | Kowa Research Institute, Inc. | $1,587 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2020 |
| 2020-12-01 | Takeda Pharmaceuticals U.S.A., Inc. | $799 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VEDOLIZUMAB SUBCUTAN | 2020 | |
| 2020-11-30 | ABBVIE INC. | $1,204 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-234 | 2020 |
| 2020-11-27 | ABBVIE INC. | $12,327 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-675 | 2020 |
| 2020-11-25 | ConvaTec Inc. | $466 | Charitable Contribution | Cash or cash equivalent | DuoDerm Device, WOUND THERAPEUTICS | 2020 | |
| 2020-11-17 | AstraZeneca Pharmaceuticals LP | $750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | LYNPARZA Drug, Oncology | 2020 | |
| 2020-11-16 | Boston Scientific Corporation | $400 | Research payment | Cash or cash equivalent | Resonate Device, Tachy | PREEMPT HF | 2020 |
| 2020-11-12 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-11-12 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-11-12 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-11-11 | Medtronic Vascular, Inc. | $715 | Research payment | Cash or cash equivalent | Arctic Front Device, Ablation | Cryo AF Global Registry | 2020 |
| 2020-11-05 | ABBVIE INC. | $286 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-234 | 2020 |
| 2020-11-05 | ABBVIE INC. | $250 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-234 | 2020 |
| 2020-11-03 | Kowa Research Institute, Inc. | $2,131 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2020 |
| 2020-11-02 | Boston Scientific Corporation | $1,701 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | SMART MSP | 2020 |
| 2020-11-02 | Merck Sharp & Dohme LLC | $41 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-10-27 | Janssen Research & Development, LLC | $4,690 | Research payment | Cash or cash equivalent | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | 2020 | |
| 2020-10-26 | Takeda Pharmaceuticals U.S.A., Inc. | $48 | Research payment | Cash or cash equivalent | A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EF | 2020 | |
| 2020-10-26 | Takeda Pharmaceuticals U.S.A., Inc. | $18 | Research payment | Cash or cash equivalent | A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EF | 2020 | |
| 2020-10-26 | Takeda Pharmaceuticals U.S.A., Inc. | $8 | Research payment | Cash or cash equivalent | A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EF | 2020 | |
| 2020-10-23 | SEAGEN INC. | $231 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2020 |
| 2020-10-21 | Regeneron Pharmaceuticals, Inc. | $9,716 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS | 2020 |
| 2020-10-21 | ABBVIE INC. | $483 | Research payment | Cash or cash equivalent | HUMIRA Biological, IMMUNOLOGY | P11-282 | 2020 |
| 2020-10-17 | Merck Sharp & Dohme LLC | $500 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-10-14 | Regeneron Pharmaceuticals, Inc. | $1,798 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS | 2020 |
| 2020-10-08 | Regeneron Pharmaceuticals, Inc. | $8,000 | Research payment | Cash or cash equivalent | A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies fo | 2020 | |
| 2020-10-08 | Regeneron Pharmaceuticals, Inc. | $3,415 | Research payment | Cash or cash equivalent | A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies fo | 2020 | |
| 2020-10-02 | Takeda Pharmaceuticals U.S.A., Inc. | $2,500 | Research payment | Cash or cash equivalent | AN OPEN-LABEL, PHASE 4 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TRIPLE COMBINATION THERAPY WITH VEDOLIZUMAB IV, ADAL | 2020 | |
| 2020-10-01 | Genentech, Inc. | $2,045 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | A PHASE III TRIAL IN ADJUVANT HER2 BC PTS | 2020 |
| 2020-09-30 | ABBVIE INC. | $4,017 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-675 | 2020 |
| 2020-09-29 | Eisai Inc. | $3,047 | Research payment | Cash or cash equivalent | Fycompa Drug, Neurology | A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial With an Open-Label Extension Phase of Perampanel as Ad | 2020 |
| 2020-09-24 | Kowa Research Institute, Inc. | $756 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2020 |
| 2020-09-21 | Boston Scientific Corporation | $375 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | SMART MSP | 2020 |
| 2020-09-17 | Ipsen Bioscience Inc. | $9,543 | Research payment | Cash or cash equivalent | An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracilLeu | 2020 | |
| 2020-09-16 | Regeneron Pharmaceuticals, Inc. | $132 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS | 2020 |
| 2020-09-09 | ABBVIE INC. | $3,845 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-533 | 2020 |
| 2020-09-08 | ABBVIE INC. | $250 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-234 | 2020 |
| 2020-09-03 | Kowa Research Institute, Inc. | $3,595 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2020 |
| 2020-09-01 | ABBVIE INC. | $7,196 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-675 | 2020 |
| 2020-08-26 | Regeneron Pharmaceuticals, Inc. | $94 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS | 2020 |
| 2020-08-25 | Medtronic Vascular, Inc. | $2,546 | Research payment | Cash or cash equivalent | Arctic Front Device, Ablation | Cryo AF Global Registry | 2020 |
| 2020-08-21 | Amgen Inc. | $925 | Research payment | In-kind items and services | Neulasta Biological, Oncology | Prospective Observational Study of Onpro vs SOC. | 2020 |
| 2020-08-05 | Regeneron Pharmaceuticals, Inc. | $3,178 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS | 2020 |
| 2020-08-05 | Oticon Medical, LLC | $160 | Education (8 payments) | Cash or cash equivalent | PONTO BONE ANCHORED HEARING SYSTEM Device, Medical Device | 2020 | |
| 2020-07-30 | ABBVIE INC. | $4,793 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-675 | 2020 |
| 2020-07-29 | ABBVIE INC. | $4,600 | Research payment | Cash or cash equivalent | HUMIRA Biological, IMMUNOLOGY | M14-347 | 2020 |
| 2020-07-27 | SEAGEN INC. | $231 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2020 |
| 2020-07-27 | SEAGEN INC. | $231 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2020 |
| 2020-07-21 | BIOTRONIK INC. | $1,000 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-07-20 | Janssen Research & Development, LLC | $8,578 | Research payment | Cash or cash equivalent | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | 2020 | |
| 2020-07-17 | Olympus America Inc. | $605 | Gift | In-kind items and services | Ultrasonic Generators Device, Urology/Gynecology | 2020 | |
| 2020-07-16 | Endologix LLC | $2,457 | Research payment | Cash or cash equivalent | ALTO Device, Cardiology/Vascular Diseases | ELEVATE IDE | 2020 |
| 2020-07-16 | Endologix LLC | $756 | Research payment | Cash or cash equivalent | ALTO Device, Cardiology/Vascular Diseases | ELEVATE IDE | 2020 |
| 2020-07-16 | Roche Products Limited | $336 | Research payment | Cash or cash equivalent | Drug | CROHN S DISEASE PROGRAM OLE | 2020 |
| 2020-07-16 | Endologix LLC | $150 | Research payment | Cash or cash equivalent | ALTO Device, Cardiology/Vascular Diseases | ELEVATE IDE | 2020 |
| 2020-07-16 | Endologix LLC | $75 | Research payment | Cash or cash equivalent | ALTO Device, Cardiology/Vascular Diseases | ELEVATE IDE | 2020 |
| 2020-07-09 | ABBVIE INC. | $536 | Research payment | Cash or cash equivalent | HUMIRA Biological, IMMUNOLOGY | P11-282 | 2020 |
| 2020-07-08 | Stryker Corporation | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | UNIVERSAL MANDIBLE Device, CRANIOMAXILLOFACIAL | 2020 | |
| 2020-07-06 | ABBVIE INC. | $10,845 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-234 | 2020 |
| 2020-07-06 | Boston Scientific Corporation | $2,876 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | SMART MSP | 2020 |
| 2020-06-30 | ABBVIE INC. | $16,692 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-675 | 2020 |
| 2020-06-28 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-06-28 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-06-26 | ABBVIE INC. | $50 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-234 | 2020 |
| 2020-06-17 | Regeneron Pharmaceuticals, Inc. | $2,401 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS | 2020 |
| 2020-06-17 | Regeneron Pharmaceuticals, Inc. | $136 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS | 2020 |
| 2020-06-17 | Allergan, Inc. | $50 | Research payment | Cash or cash equivalent | A SAFETY AND EFFICACY STUDY OF ABICIPAR PEGOL IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | 2020 | |
| 2020-06-17 | Allergan, Inc. | $49 | Research payment | Cash or cash equivalent | A SAFETY AND EFFICACY STUDY OF ABICIPAR PEGOL IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | 2020 | |
| 2020-06-16 | MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA, INC. | $10,000 | Research payment | Cash or cash equivalent | A STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY , PHARMACOKINETICS OF SINGLE ASCENDING DOSE OF MT-3921 IN SUBJECTS WITH | 2020 | |
| 2020-06-12 | Daiichi Sankyo Inc. | $642 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | ENVISAGE | 2020 |
| 2020-06-11 | SEAGEN INC. | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | PADCEV Biological, Oncology | 2020 | |
| 2020-06-09 | BIOTRONIK INC. | $212 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-06-09 | BIOTRONIK INC. | $207 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-06-09 | BIOTRONIK INC. | $207 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-06-09 | BIOTRONIK INC. | $207 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-06-09 | BIOTRONIK INC. | $207 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-06-09 | BIOTRONIK INC. | $207 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-06-09 | BIOTRONIK INC. | $207 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-06-09 | BIOTRONIK INC. | $207 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-06-09 | BIOTRONIK INC. | $207 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-06-09 | BIOTRONIK INC. | $207 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-06-09 | BIOTRONIK INC. | $207 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-06-09 | BIOTRONIK INC. | $166 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-06-04 | Premia Spine, Ltd. | $1,801 | Research payment | Cash or cash equivalent | TOPS | A Clinical Study to Assess the Safety and Effectiveness of the Premia Spine TOPS System | 2020 |
| 2020-05-29 | ABBVIE INC. | $5,810 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-675 | 2020 |
| 2020-05-28 | PFIZER INC. | $1,000 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-05-28 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-05-26 | ABBVIE INC. | $463 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-675 | 2020 |
| 2020-05-21 | Ipsen Bioscience Inc. | $8,750 | Research payment | Cash or cash equivalent | ONIVYDE Drug, Oncology | An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracilLeu | 2020 |
| 2020-05-20 | Regeneron Pharmaceuticals, Inc. | $1,023 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS | 2020 |
| 2020-05-20 | Regeneron Pharmaceuticals, Inc. | $42 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS | 2020 |
| 2020-05-19 | Amgen Inc. | $750 | Research payment | Cash or cash equivalent | Ph 2b UC Study | 2020 | |
| 2020-05-19 | Takeda Pharmaceuticals U.S.A., Inc. | $109 | Research payment | Cash or cash equivalent | A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EF | 2020 | |
| 2020-05-19 | Takeda Pharmaceuticals U.S.A., Inc. | $11 | Research payment | Cash or cash equivalent | A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EF | 2020 | |
| 2020-05-07 | Medtronic Vascular, Inc. | $2,994 | Research payment | Cash or cash equivalent | Arctic Front Device, Ablation | Cryo AF Global Registry | 2020 |
| 2020-05-07 | ABBVIE INC. | $1,593 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-234 | 2020 |
| 2020-05-01 | PFIZER INC. | $1,000 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-04-27 | Regeneron Pharmaceuticals, Inc. | $3,000 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS | 2020 |
| 2020-04-27 | Regeneron Pharmaceuticals, Inc. | $742 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS | 2020 |
| 2020-04-27 | Regeneron Pharmaceuticals, Inc. | $478 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS | 2020 |
| 2020-04-27 | Regeneron Pharmaceuticals, Inc. | $136 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS | 2020 |
| 2020-04-24 | Medtronic Vascular, Inc. | $3,875 | Research payment | Cash or cash equivalent | Arctic Front Device, Ablation | Cryo AF Global Registry | 2020 |
| 2020-04-23 | ABBVIE INC. | $3,187 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-234 | 2020 |
| 2020-04-23 | Janssen Research & Development, LLC | $1,876 | Research payment | Cash or cash equivalent | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | 2020 | |
| 2020-04-23 | ABBVIE INC. | $1,593 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-234 | 2020 |
| 2020-04-21 | Boston Scientific Corporation | $8,274 | Research payment | Cash or cash equivalent | Resonate Device, Tachy | PREEMPT HF | 2020 |
| 2020-04-17 | ConvaTec Inc. | $311 | Charitable Contribution | Cash or cash equivalent | DuoDerm Device, WOUND THERAPEUTICS | 2020 | |
| 2020-04-14 | Regeneron Pharmaceuticals, Inc. | $2,989 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS | 2020 |
| 2020-04-14 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-04-14 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-04-14 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-04-14 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-04-13 | ABBVIE INC. | $50 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-234 | 2020 |
| 2020-04-06 | Boston Scientific Corporation | $1,877 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | SMART MSP | 2020 |
| 2020-03-31 | ABBVIE INC. | $1,878 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-234 | 2020 |
| 2020-03-25 | ABBVIE INC. | $6,330 | Research payment | Cash or cash equivalent | HUMIRA Biological, IMMUNOLOGY | P11-282 | 2020 |
| 2020-03-18 | Daiichi Sankyo Inc. | $642 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | ENVISAGE | 2020 |
| 2020-03-18 | Daiichi Sankyo Inc. | $642 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | ENVISAGE | 2020 |
| 2020-03-18 | Daiichi Sankyo Inc. | $642 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | ENVISAGE | 2020 |
| 2020-03-18 | Daiichi Sankyo Inc. | $642 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | ENVISAGE | 2020 |
| 2020-03-12 | Janssen Research & Development, LLC | $8,036 | Research payment | Cash or cash equivalent | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | 2020 | |
| 2020-03-11 | AstraZeneca Pharmaceuticals LP | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | LOKELMA Drug, Cardiovascular and Metabolism | 2020 | |
| 2020-03-11 | SEAGEN INC. | $270 | Research payment | Cash or cash equivalent | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2020 | |
| 2020-03-11 | SEAGEN INC. | $163 | Research payment | Cash or cash equivalent | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2020 | |
| 2020-03-06 | SEAGEN INC. | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | PADCEV Biological, Oncology | 2020 | |
| 2020-03-05 | Regeneron Pharmaceuticals, Inc. | $5,359 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS | 2020 |
| 2020-03-05 | ABBVIE INC. | $28 | Research payment | Cash or cash equivalent | HUMIRA Biological, IMMUNOLOGY | P11-282 | 2020 |
| 2020-03-04 | Premia Spine, Ltd. | $1,518 | Research payment | Cash or cash equivalent | TOPS | A Clinical Study to Assess the Safety and Effectiveness of the Premia Spine TOPS System | 2020 |
| 2020-03-03 | ABBVIE INC. | $50 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-234 | 2020 |
| 2020-03-02 | ABBVIE INC. | $13,658 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-675 | 2020 |
| 2020-02-26 | Incyte Corporation | $700 | Research payment | Cash or cash equivalent | Evaluation Of Ruxolitinib And Azacytidine Combination As A Therapy For Patients With Myelofibrosis And Myelodysplastic S | 2020 | |
| 2020-02-25 | ABBVIE INC. | $583 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-675 | 2020 |
| 2020-02-25 | Becton, Dickinson and Company | $106 | Education | In-kind items and services | 2020 | ||
| 2020-02-24 | ABBVIE INC. | $1,027 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-234 | 2020 |
| 2020-02-20 | Regeneron Pharmaceuticals, Inc. | $3,135 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS | 2020 |
| 2020-02-20 | ABBVIE INC. | $81 | Research payment | Cash or cash equivalent | HUMIRA Biological, IMMUNOLOGY | P11-282 | 2020 |
| 2020-02-19 | SEAGEN INC. | $2,455 | Research payment | Cash or cash equivalent | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2020 | |
| 2020-02-18 | SANOFI US SERVICES INC. | $2,000 | Research payment | Cash or cash equivalent | An Open Label Randomized Phase 2 Trial of SAR439859, Versus Endocrine Monotherapy as Per Physician's Choice in Premenopa | 2020 | |
| 2020-02-18 | Boston Scientific Corporation | $680 | Research payment | Cash or cash equivalent | GENERAL - TACHY Device, TACHY | LSS OF 4 SITE | 2020 |
| 2020-02-18 | Boston Scientific Corporation | $500 | Research payment | Cash or cash equivalent | GENERAL - TACHY Device, TACHY | LSS OF 4 SITE | 2020 |
| 2020-02-18 | Boston Scientific Corporation | $264 | Research payment | Cash or cash equivalent | GENERAL - TACHY Device, TACHY | LSS OF 4 SITE | 2020 |
| 2020-02-13 | Allergan, Inc. | $748 | Research payment | Cash or cash equivalent | A SAFETY AND EFFICACY STUDY OF ABICIPAR PEGOL IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | 2020 | |
| 2020-02-13 | ABBVIE INC. | $100 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-234 | 2020 |
| 2020-02-10 | Medtronic Vascular, Inc. | $16,295 | Research payment | Cash or cash equivalent | Arctic Front Device, Ablation | Cryo AF Global Registry | 2020 |
| 2020-02-04 | Premia Spine, Ltd. | $2,520 | Research payment | Cash or cash equivalent | TOPS | A Clinical Study to Assess the Safety and Effectiveness of the Premia Spine TOPS System | 2020 |
| 2020-02-04 | Takeda Pharmaceuticals U.S.A., Inc. | $570 | Research payment | Cash or cash equivalent | A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH | 2020 | |
| 2020-02-04 | Takeda Pharmaceuticals U.S.A., Inc. | $500 | Research payment | Cash or cash equivalent | A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH | 2020 | |
| 2020-01-31 | ABBVIE INC. | $13,650 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-234 | 2020 |
| 2020-01-31 | ABBVIE INC. | $1,297 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-234 | 2020 |
| 2020-01-31 | GE HEALTHCARE | $1,154 | Charitable Contribution | Cash or cash equivalent | 2020 | ||
| 2020-01-31 | ABBVIE INC. | $702 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-675 | 2020 |
| 2020-01-29 | Amgen Inc. | $17,666 | Research payment | Cash or cash equivalent | Neulasta Biological, Oncology | Prospective Observational Study of Onpro vs SOC. | 2020 |
| 2020-01-29 | ABBVIE INC. | $55 | Research payment | Cash or cash equivalent | HUMIRA Biological, IMMUNOLOGY | P11-282 | 2020 |
| 2020-01-27 | Novartis Pharmaceuticals Corporation | $32,035 | Research payment | Cash or cash equivalent | BEOVU Drug, OPHTHALMOLOGY | A TWO YEAR, RANDOMIZED, DOUBLE MASKED, MULTICENTER, PHASE III STUDY ASSESSING THE EFFICACY AND SAFETY OF BROLUCIZUMAB VE | 2020 |
| 2020-01-27 | E.R. Squibb & Sons, L.L.C. | $11,355 | Research payment | Cash or cash equivalent | EMPLICITI Biological, Oncology | Prospective REsearch Assessment in Multiple Myeloma: an OBservationaL Evaluation (PREAMBLE) | 2020 |
| 2020-01-23 | Genentech, Inc. | $2,045 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | A PHASE III TRIAL IN ADJUVANT HER2 BC PTS | 2020 |
| 2020-01-23 | ABBVIE INC. | $1,593 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-234 | 2020 |
| 2020-01-22 | Celgene Corporation | $8,336 | Research payment | Cash or cash equivalent | PhIII Yellowstone Induction Study # 1 OZANIMOD in Moderate to Severe CD (RPC01-3201) (BMS Study Number: IM047-P14) | 2020 | |
| 2020-01-22 | Incyte Corporation | $5,467 | Research payment | Cash or cash equivalent | Evaluation Of Ruxolitinib And Azacytidine Combination As A Therapy For Patients With Myelofibrosis And Myelodysplastic S | 2020 | |
| 2020-01-22 | ABBVIE INC. | $3,132 | Research payment | Cash or cash equivalent | HUMIRA Biological, IMMUNOLOGY | P11-282 | 2020 |
| 2020-01-21 | Janssen Research & Development, LLC | $28,493 | Research payment | Cash or cash equivalent | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | 2020 | |
| 2020-01-21 | Regeneron Pharmaceuticals, Inc. | $3,042 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS | 2020 |
| 2020-01-21 | Janssen Research & Development, LLC | $53 | Research payment | In-kind items and services | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | 2020 | |
| 2020-01-21 | Janssen Research & Development, LLC | $39 | Research payment | In-kind items and services | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | 2020 | |
| 2020-01-21 | Janssen Research & Development, LLC | $24 | Research payment | In-kind items and services | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | 2020 | |
| 2020-01-21 | Janssen Research & Development, LLC | $12 | Research payment | In-kind items and services | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | 2020 | |
| 2020-01-21 | Janssen Research & Development, LLC | $7 | Research payment | In-kind items and services | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | 2020 | |
| 2020-01-21 | Janssen Research & Development, LLC | $7 | Research payment | In-kind items and services | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | 2020 | |
| 2020-01-21 | Janssen Research & Development, LLC | $2 | Research payment | In-kind items and services | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | 2020 | |
| 2020-01-21 | Janssen Research & Development, LLC | $1 | Research payment | In-kind items and services | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | 2020 | |
| 2020-01-21 | Janssen Research & Development, LLC | $1 | Research payment | In-kind items and services | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | 2020 | |
| 2020-01-16 | Takeda Pharmaceuticals U.S.A., Inc. | $11,961 | Research payment | Cash or cash equivalent | A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EF | 2020 | |
| 2020-01-15 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-01-15 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-01-13 | ABBVIE INC. | $1,794 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-234 | 2020 |
The latest 200 records of 208.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Urbana, IL, county Champaign County, IL, state Illinois; placed by its city name.
| Measure | Place (city or town) Urbana, IL | County Champaign County, IL | State Illinois |
|---|---|---|---|
| Population B01003 | 39,341 | 208,741 | 12,694,798 |
| Population, 2020 census P1 | 38,336 | 205,865 | 12,812,508 |
| Median age B01002 | 26.1 | 30.7 | 39.0 |
| Under 18 B01001 | 13.2% | 19.1% | 21.8% |
| 65 and over B01001 | 11.5% | 13.9% | 17.0% |
| Households B11001 | 16,856 | 85,472 | 5,036,449 |
| Foreign born B05002 | 21.2% | 14.2% | 14.7% |
| Median household income B19013 | $45,346 | $63,683 | $83,390 |
| Median family income B19113 | $86,209 | $100,396 | $106,018 |
| Per capita income B19301 | $32,592 | $38,439 | $46,406 |
| Poverty rate B17001 | 28.0% | 19.1% | 11.8% |
| Unemployment rate B23025 | 4.7% | 4.3% | 5.8% |
| Civilian labor force B23025 | 20,316 | 104,876 | 6,652,134 |
| Mean commute (minutes) B08013 | 14.2 | 16.9 | 27.8 |
| Bachelor's degree or higher B15003 | 56.7% | 46.2% | 37.8% |
| Housing units B25001 | 19,228 | 95,115 | 5,457,452 |
| Owner-occupied B25003 | 37.3% | 54.0% | 67.1% |
| Renters B25003 | 62.7% | 46.0% | 32.9% |
| Median home value B25077 | $184,900 | $211,500 | $263,300 |
| Median gross rent B25064 | $972 | $1,051 | $1,274 |
| White, not Hispanic B03002 | 52.9% | 62.4% | 58.1% |
| Black B03002 | 18.7% | 13.4% | 13.3% |
| Hispanic or Latino B03002 | 10.1% | 8.3% | 18.8% |
| Asian B03002 | 14.2% | 11.4% | 5.9% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.1% |
Economy now FRED unemployment 4.6% in Sep 2026 (4.5% a year earlier); per capita personal income $78,987 in 2025, up 28% in five years (+3.1% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Urbana, IL.
Comments